Effect of SBG in Patients With Breast Cancer
Effect of SBG in Patients With Breast Cancer
This study is set up to determine whether soluble beta-glucan (SBG) has

 -  unfavourable side effects

 -  beneficial treatment effects when given in combination with standard antibody and
 chemotherapy to patients with breast cancer.
Inclusion Criteria:

 1. Women with histologically/cytologically confirmed locally advanced or metastatic
 breast cancer

 2. Primary tumor or metastases are HER2-ICH3+ or FISH+

 3. Measurable or non-measurable disease

 4. The patients must not have received treatment with the combination trastuzumab and
 vinorelbine previously

 5. Expected lifetime of more than 12 weeks

 6. Age ≥ 18 years

 7. Performance status ≤ 2 according to World Health Organization (WHO) scale

 8. The patient must be able to comply with the protocol

 9. Verbal and written informed consent

 Exclusion Criteria:

 1. Women who are pregnant or breast-feeding. A negative pregnancy test must be provided
 during the screening period for fertile women. Fertile women must use effective
 contraceptive methods

 2. Clinical symptoms indicating central nervous system involvement

 3. Other current or former malignant disease, with the exception of adequately treated
 and cured carcinoma in situ cervicis uteri and basocellular skin carcinomas

 4. Left ventricular ejection fraction (LVEF) < 50% of normal range

 5. Reduced bone marrow function defined by leukocyte counts < 3.0 x 109/l and neutrophil
 counts < 1.5 x 109/l, or thrombocyte counts ≤ 100 x 109/l

 6. Reduced liver function defined by bilirubin > 3 x upper normal limit and/or ASAT/ALAT
 > 3 x upper normal limit and/or alkaline phosphatase > 3 x upper normal limit.

 7. Reduced renal function defined by serum creatinine > 2 x upper normal limit